After $59M round, CRISPR startup launches with plans to tackle heart disease
May 07, 2019 at 06:01 AM EDT
A new gene editing company founded by two Harvard scientists and one of the men behind Editas Medicine has launched with nearly $59 million to develop a single treatment for the leading cause of death worldwide.
